CA

Protein engineering to target tumor-stroma interactions in NSCLC

Targeted Therapeutics Research Award
This grant was funded in part by Upstage Lung Cancer.
Alejandro Sweet-Cordero, MD
Stanford University
Stanford
CA
Jennifer Cochran, PhD
Stanford University
Stanford
CA
Lung cancer cells depend on continuous cross-talk with other cells around them. Drs. Sweet-Cordero and Cochran will use decoy proteins to intercept and disable this essential molecular communications between the tumor and its environment, thereby destroying the cancer.

Activating phagocytosis to inhibit small cell lung carcinoma

Targeted Therapeutics Research Award
Julien Sage, PhD
Stanford University
Stanford
CA
Irving Weissman, MD
Stanford University
Stanford
CA
Drs. Sage and Weissman will test a new immunotherapy to boost the arsenal of immune cells to combat SCLC. They will work to disable a protein on the cancer cells that inhibits macrophages, a type of immune cell that can engulf and destroy cancer cells. This will boost the killing capacity of macrophages and recruit more immune cells to the area by the tumor.

In-vivo and in-vitro diagnostics to improve lung cancer care

Career Development Award
Viswam S. Nair, MD
Stanford University
Stanford
CA

Dr. Nair is developing a blood test to help determine whether a pulmonary nodule seen on a PET-scan imaging screen is cancerous. The goal of this test, which will make use of circulating molecular biomarkers, is to accurately determine which patients are most likely to have lung cancer and, therefore, should have biopsies or surgery.